Conservative Anterior Partial Coverage CAD/CAM Restoration.

Computer-aided design and manufacturing technology enables practitioners to create, in a single appointment, indirect restorations that are esthetic and functionally unique to the patient's situation. The popular effort to perform minimally invasive dentistry using digital techniques with chairside milling can lead dentists to novel individualized restorative treatment. This article demonstrates a conservative anterior partial coverage restoration, utilizing both digital technology and chairside ceramic characterization to achieve an optimal esthetic outcome while preserving healthy tooth structure.

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.

PURPOSE: To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment. PATIENTS AND METHODS: In this double-blind, double-dummy, parallel-group study, postmenopausal patients were randomized to receive either an intramuscular injection of fulvestrant 250 mg once monthly or a daily oral dose of anastrozole 1 mg. The primary end point was time to progression (TTP). Secondary end points included objective response (OR) rate, duration of response (DOR), and tolerability. RESULTS: Patients (n = 400) were followed for a median period of 16.8 months. Fulvestrant was as effective as anastrozole in terms of TTP (hazard ratio, 0.92; 95.14% confidence interval [CI], 0.74 to 1.14; P =.43); median TTP was 5.4 months with fulvestrant and 3.4 months with anastrozole. OR rates were 17.5% with both treatments. Clinical benefit rates (complete response + partial response + stable disease > or = 24 weeks) were 42.2% for fulvestrant and 36.1% for anastrozole (95% CI, -4.00% to 16.41%; P =.26). In responding patients, median DOR (from randomization to progression) was 19.0 months for fulvestrant and 10.8 months for anastrozole. Using all patients, DOR was significantly greater for fulvestrant compared with anastrozole; the ratio of average response durations was 1.35 (95% CI, 1.10 to 1.67; P < 0.01). Both treatments were well tolerated. CONCLUSION: Fulvestrant was at least as effective as anastrozole, with efficacy end points slightly favoring fulvestrant. Fulvestrant represents an additional treatment option for postmenopausal women with advanced breast cancer whose disease progresses on tamoxifen therapy.

Comparison of six Australian isolates of Bovine herpes virus 2 based on UL24 gene after a passage in MDBK cells.

A region of the UL24 gene of six Australian field isolates of Bovine herpesvirus 2 (BHV-2) was sequenced after a passage in Madin-Darby bovine kidney (MDBK) cells by polymerase chain reaction (PCR). While the PCR product covered the first half of the UL24 gene, a particular interest was focused on the 274-297 nucleotide (nt) region in which a two nt deletion had previously been detected in the BHM-1 strain of BHV-2. Most isolates tested did not generate any defective UL24 genes during the passage. However, a third of the UL24 genes of BHM-1 strain contained the two nts deletion, but only when a high multiplicity of infection (MOI) was used. Also in the isolate 554 at least a half of the UL24 genes were found to be altered independently of the MOT used. These UL24 genes had an insertion of four nts within the 274-297 nt region. The predicted truncation of the UL24 protein of both viruses occurred at the same stop codon. The region of the gene in which these mutations of the UL24 gene occurred is common to all herpesviruses.

Effect of antimicrobial factors in human milk on rhinoviruses and milk-borne cytomegalovirus in vitro.

Various antimicrobial factors present in human milk were tested for in-vitro antiviral activity against three rhinoviruses (two clinical isolates and rhinovirus 2) and an isolate of cytomegalovirus (CMV) from human milk. These factors included the gangliosides GM1, 2 and 3, sialyl-lactose, chondroitin sulphates A, B and C, prostaglandins E2 and F2alpha, monolaurin, vitamin A and the protein lactoferrin. All were tested for their ability to inhibit growth of the viruses in cell culture. Human milk was also tested for antiviral activity against these viruses. Only vitamin A, monolaurin and lactoferrin inhibited the growth of CMV, whereas both prostaglandins enhanced the growth of this virus at least four-fold. CMV infects infants from milk but, nevertheless, the milk-borne CMV isolate showed no special resistance to any of the antiviral factors tested. None of the compounds inhibited or enhanced the growth of the rhinoviruses. However, human milk decreased the growth of some of the rhinoviruses and specific secretory immunoglobulin A (sIgA) neutralised the virus.

Effect of compounds with antibacterial activities in human milk on respiratory syncytial virus and cytomegalovirus in vitro.

The effect of some antibacterial compounds present in human milk were tested for antiviral activity against respiratory syncytial virus, Semliki Forest virus and cytomegalovirus. These included the gangliosides GM1, GM2 and GM3, sialyl-lactose, lactoferrin and chondroitin sulphate A, B and C, which were all tested for their ability to inhibit the viruses in cell culture. Of the compounds tested, only the ganglioside GM2, chondroitin sulphate B and lactoferrin inhibited the absorption and growth of respiratory syncytial virus in cell culture, and none inhibited the growth of Semliki Forest virus, indicating that lipid antiviral activity was not associated with any of the gangliosides. While the concentrations of these two compounds required to inhibit respiratory syncytial virus were in excess of those present in human milk, sialyl-lactose concentrations similar to those present in human milk increased the growth of cytomegalovirus. Lactoferrin was confirmed as inhibiting both respiratory syncytial virus and cytomegalovirus growth in culture even when used at lower concentrations than those present in human milk. The antiviral activities of GM2, chondroitin sulphate B and lactoferrin were tested when added to an infant formula. Lactoferrin continued to have antiviral activity against cytomegalovirus, but a lower activity against respiratory syncytial virus; ganglioside GM2 and chondroitin sulphate B still maintained antiviral activity against respiratory syncytial virus.

Loss of thymidine kinase activity due to a base deletion in a candidate vaccine strain of bovine herpesvirus 2.

The nucleotide (nt) sequence of the thymidine kinase (TK) gene (a 918 nt long coding region) of two TK-deficient (TK) strains of bovine herpesvirus 2 (BHV-2) was determined. The candidate vaccine strain C290BU5, which was no longer able to cause disease, was found to have an A deletion after nt 887 of the TK gene with a predicted change of His 296 to Pro, altering the last 10 amino acids (aa) and extending the gene by another 34 aa. The strain which still caused disease, C290BU3, had a T insertion after nt 16 causing a predicted chain termination after only 16 aa.

Effect of human milk prostaglandins and lactoferrin on respiratory syncytial virus and rotavirus.

The effect of lactoferrin and prostaglandins E and F2 alpha on the growth of rotavirus and respiratory syncytial virus in cell culture was investigated. Lactoferrin inhibited the growth of respiratory syncytial virus at a concentration tenfold lower than that normally present in human milk. The prostaglandins had no effect on either virus growth, even at a concentration of 100-fold more than that found in human milk. Lactoferrin may have some antiviral properties in human milk in addition to its known antibacterial functions.

The effect of serial in vivo passage on the expression of virulence and DNA stability of an infectious laryngotracheitis virus strain of low virulence.

The effect of 35 serial passages in vivo on an infectious laryngotracheitis virus strain of low virulence was examined in terms of effect on virulence and DNA stability. Within 3 passages in live chickens there was evidence of increasing respiratory distress. Severe respiratory distress (with death in some cases) was observed after the 6th passage, except when there appeared to be a transient decline in pathogenicity following short term storage of the virus inoculum at -70 degrees C. Restriction endonuclease analysis of viral DNA derived from the original inoculum and the final passage did not reveal any genomic alteration. It is postulated that there is a potential for live ILTV vaccines to cause outbreaks of clinical disease in the event of inadequate or incomplete vaccination procedures.

Antimicrobial factors and microbial contaminants in human milk: recent studies.

An overview of recent studies of antimicrobial factors and microbial contaminants found in human milk is presented. The incidence of gastrointestinal and respiratory infections in infants receiving human milk continues to be lower than in those not breast-fed due to the presence of specific antibody and possibly anti-adhesion factors in the milk. Whether the many other antimicrobial factors, which have been shown to be active in vitro or in animal model systems, have any influence on infant infections is still not clear. Microbial contaminants in human milk are rare, as are associated infant infections from the milk. However, some contaminants such as cytomegalovirus are commonly transferred to infants from the milk of seropositive mothers, fortunately without any adverse effects in the infants. Human T-lymphotropic virus type 1 is transferred via human milk in endemic areas, human milk being the main source of mother-to-infant transmission. While some reports suggest human immunodeficiency virus type 1 transfer may occur through human milk, this is not the predominant mode of transmission to infants.

Bovine herpes mammalitis virus thymidine kinase gene.

Bovine herpes mammillitis virus (BHMV) codes for a thymidine kinase (Tk), the gene for which is located in a 2.6 kb SalI restriction endonuclease fragment with a map unit of 0.2-0.32. This particular DNA fragment can transfect LTk-mouse cells and convert them to Tk+. The gene position of BHMV Tk would suggest another homologous gene map position for BHMV and herpes simplex virus (HSV).

Prevalence of antibody to human T-lymphotropic virus type-1 (HLTV-1) in Australian aborigines, and detection in Indonesian sera.

The first finding of antibody to human T-lymphotropic virus type 1 in Australia, specifically in Australian Aborigines, is reported. The overall results suggest that this is a new area to be added to the known endemic areas for this virus. Antibody prevalence in each of two widely separated areas was found to be approximately 16% in 1977, and in one of these areas this had increased to approximately 34% in 1984/86. In this area no antibody to this virus was detected in children under 4 years of age.

PIP: The 1st finding of antibody-to-human T-lymphotropic virus type 1 in Australia, specifically in Australian Aborigines, is reported here. Overall results suggest that this is a new area to be added to those known endemic areas for this virus. Antibody prevalence in each of 2 widely separated areas were found to be approximately 16% in 1977, and in 1 of these areas, this increased to approximately 34% in 1984-86. No antibody to this virus was detected in this area in children under 4 years of age.